STD Testing Market Overview 2030
The STD testing market size accounted for $91,445.93 Million in 2020, and is expected to reach $1,50,445.01 Million by 2030, registering a CAGR of 5.1% from 2021 to 2030. Sexually transmitted diseases (STDs) are infections transmitted from an infected person to an uninfected person through sexual contact. The contact is usually vaginal, oral, or anal sex. But sometimes they can spread through other intimate physical contact. This is because some STDs, like herpes and HPV, are spread by skin-to-skin contact. It is caused by bacteria, viruses, or parasites. Examples include gonorrhea, genital herpes, human papillomavirus infection, HIV/AIDS, chlamydia, and syphilis. High incidences of STDs and increased governmental support are the factors that drive the sexually transmitted diseases (STD) testing market growth.
Rise in awareness among people, and patient education are the other pivotal factors that fuel the growth of the sexually transmitted diseases (STD) testing market. In addition, rise in prevalence of STD's globally, increase in patient awareness through education campaigns, and surge in government initiatives are anticipated to drive the market growth. STDs have witnessed substantial growth in their prevalence and incidents in the past decade. With increase in prevalence, respective countries across the world are focusing on implementation of national screening programs to expand the coverage of STD diagnosis. Moreover, reimbursement policies have also been favorable for STD services. These factors are significantly driving the growth of the global STD testing market.
The sexually transmitted diseases testing market is segmented on the basis of diseases type, location of testing, and region. By disease type, the market is categorized into chlamydia, gonorrhea, herpes simplex virus, syphilis, human papillomavirus (HPV), and other diseases (human immunodeficiency virus (HIV), chancroid, trichomoniasis, and hepatitis B). By location of testing, the market is bifurcated into laboratory testing, and point of care (POC) testing. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
What is the Impact of COVID-19 Pandemic on the sexually transmitted diseases testing market?
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, there are only a few vaccines that received emergency approvals for COVID-19 treatment or prevention. Thus, social-distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the sexually transmitted diseases (STD) testing market. During the early months of the COVID-19 pandemic reports of sexually transmitted infections decreased due to disruptions to health care and sexually transmitted infections testing services, reports the CDC. Reduced access to testing and diagnoses may have led some people to unwittingly spread infection. As clinics reopen, infections rates are again are on rise.
Due to limited intensive care resources, efforts focused primarily on protecting access to critical care services. Preventive services were reduced, and many non-urgent visits were significantly delayed or changed to virtual platforms to preserve personal protective equipment supply and limit patients’ and clinical staff’s exposure risks. All time high cases of chlamydia and gonorrhea were reported in 2019 in the United States, and more than half of these occur among people aged 15-24, but after pandemic sexually transmitted infections testing cases has been decreased.
Disease Type Segment Review
Depending on disease type, the sexually transmitted diseases (STD) testing market is divided into chlamydia, gonorrhea, herpes simplex virus, syphilis, human papillomavirus (HPV) and other diseases (human immunodeficiency virus (HIV), chancroid, trichomoniasis, and hepatitis B). The chlamydia segment accounted for the majority of the STD testing market share in 2020, owing to lack of awareness about sexually transmitted diseases among population and lack of barrier protection.
By Disease Type
Chlamydia Testing segment held a dominant position in 2020 and Gonorrhoea will maintain the lead over the forecast period.
Location of Testing Segment Review
By location of testing, the market is segmented into laboratory testing and point of care (POC) testing. The laboratory testing segment accounted for the majority of market share of the global STD testing market in 2020 and is expected to remain dominant during the forecast period; in addition, most of the cases of diagnostic testing are carried out in the labs which are expected to further fuel the demand for STD testing.
By Location Of Testing
Laboratory Testing segment is projected as one of the most lucrative segment.
Region Segment Review
By region, the STD testing market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. Asia-Pacific dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to the increase in case of sexual transmitted diseases in emerging countries. In addition, increase in patient awareness through education campaigns and growing government initiatives are anticipated to drive the STD testing market growth.
By Region
Asia-Pacific was holding a dominant position in 2020 and Asia-Pacific will maintain the lead over the analysis period.
This report provides comprehensive competitive analysis and profiles of prominent market players such as Abbott laboratories, Becton Dickinson Company, BioMérieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic, Inc., Orasure Technologies, Inc., Roche Holding AG and Thermo Fisher Scientific Inc.
Key Benefits for Stakeholders
- This report provides a detailed quantitative analysis of the current STD testing market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing sexually transmitted diseases (STD) testing market opportunities.
- An in-depth sexually transmitted diseases testing market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
- A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
- The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
- An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
- Key market players within the STD testing market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the sexually transmitted diseases testing market.
Sexually Transmitted Diseases (STD) Testing Market Report Highlights
| Aspects | Details |
 By DISEASE TYPE |
|
 By LOCATION OF TESTING |
|
 By Region |
|
 Key Market Players | ROCHE HOLDINGS AG, ABBOTT LABORATORIES, HOLOGIC INC., ORASURE TECHNOLOGIES, INC., DIASORIN MOLECULAR LLC, BIOMÉRIEUX, INC., BIO-RAD LABORATORIES INC., DANAHER CORPORATION, BECTON DICKINSON COMPANY, THERMO FISHER SCIENTIFIC (AFFYMETRIX) |
Analyst Review
The adoption of STD is anticipated to witness significant growth due to high prevalence of STDs in the developing nations. Moreover, the STD testing market has gained immense interest in the healthcare industry due to its major role in the diagnosis and treatment of highly prevalent STDs. Asia-Pacific is projected to register the highest growth rate in the global STD testing market due to massive increase in population, and high prevalence of STDs.
Rise in incidences of STDs, implementation of national screening programs, and support in reimbursement for STD testing are the major factors that drive the market growth. However, there is social stigma associated with patients visiting specialized STD clinics that refrain patients from STD diagnosis. Moreover, huge proportion of patients infected with STDs are based in out-of-reach geographic areas, which significantly limits the diagnosis of STDs. Such factors are expected to restrain the market growth.
The total market value of STD Testing Market is $91445.94 million in 2020
The forecast period in the report is from 2021 to 2030
The market value of STD Testing Market in 2030 was $150445.01 Million
The base year for the report is 2020
Yes, STD Testing companies are profiled in the report
The top companies that hold the market share in STD Testing Market are Abbott laboratories, Becton Dickinson Company, BioMérieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic, Inc., Orasure Technologies, Inc., Roche Holding AG and Thermo Fisher Scientific Inc.
The key trends in the STD Testing Market are rise in prevalence of STD's globally, increase in patient awareness through education campaigns, and surge in government initiatives are anticipated to drive the market growth.
Loading Table Of Content...
